Bridgeway Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Bridgeway Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$319K	Buy	+123,000	New	+$364K	0.01%	967

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bridgeway Capital Management's AVXL Position: Q2 2026 in Review

Bridgeway Capital Management opened a new position in Anavex Life Sciences (AVXL) in Q2 2026: 123,000 shares worth $319K. The stake represents 0.01% of the portfolio and ranks #967 among its holdings.

179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

Bridgeway Capital Management held 123,000 shares of Anavex Life Sciences worth $319K as of Q2 2026.
Anavex Life Sciences was a new Bridgeway Capital Management position in Q2 2026.
Anavex Life Sciences made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #967 holding.
179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.